Abstract

Enzyme nanoencapsulation holds an enormous potential to develop new therapeutic approaches to a large set of human pathologies including cancer, infectious diseases and inherited metabolic disorders. However, enzyme formulation has been limited by the need to maintain the catalytic function, which is governed by protein conformation. Herein we report the rational design of a delivery system based on chitosan for effective encapsulation of a functionally and structurally complex human metabolic enzyme through ionic gelation with tripolyphosphate. The rationale was to use a mild methodology to entrap the multimeric multidomain 200 kDa human phenylalanine hydroxylase (hPAH) in a polyol-like matrix that would allow an efficient maintenance of protein structure and function, avoiding formulation stress conditions. Through an in silico and in vitro based development, the particulate system was optimized with modulation of nanomaterials protonation status, polymer, counterion and protein ratios, taking into account particle size, polydispersity index, surface charge, particle yield production, protein free energy of folding, electrostatic surface potential, charge, encapsulation efficiency, loading capacity and transmission electron microscopy morphology. Evaluation of the thermal stability, substrate binding profile, relative enzymatic activity, and substrate activation ratio of the encapsulated hPAH suggests that the formulation procedure does not affect protein stability, allowing an effective maintenance of hPAH biological function. Hence, this study provides an important framework for an enzyme formulation process.

Highlights

  • The advent of recombinant DNA technology revolutionized the therapeutic approaches to a vast number of unmet medical disorders by boosting the development of new biologic pharmaceutical entities, including peptide and proteins [1]

  • Chitosan is a natural cationic polymer derived from the N-deacetylation of chitin, comprised of β-(1-4)-2-amino-2-deoxy-D-glucopyranose and a varying amount of β-(1-4)2-acetamino-2-deoxy-D-glucopyranose residues according to its deacetylation degree (DD)

  • Bridging the knowledge obtained by in silico and in vitro data, we were able to detect the critical parameters that impacted the ionic gelation of CS, TPP and human phenylalanine hydroxylase (hPAH) and optimize a colloidal system that usually renders entropic large mean nanoparticle sizes and broader distributions

Read more

Summary

Introduction

The advent of recombinant DNA technology revolutionized the therapeutic approaches to a vast number of unmet medical disorders by boosting the development of new biologic pharmaceutical entities, including peptide and proteins [1]. According to their function and biomedical application, protein therapeutics have been grouped in four classes [2]: protein therapeutics with enzymatic or regulatory activity (Group I); protein therapeutics with special targeting activity (Group II); protein vaccines (Group III); and protein diagnostics (Group IV).

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call